Prostate Cancer | Specialty

Dr. Tagawa on Remaining Questions With PSMA-Targeted Radionuclide Therapy in mCRPC

March 28th 2020

Scott T. Tagawa, MD, MS, discusses remaining questions regarding treatment selection and PSMA imaging in metastatic castration-resistant prostate cancer.

Dr. Antonarakis on PD-1/PD-L1 Monotherapy in Prostate Cancer

March 28th 2020

Emmanuel S. Antonarakis, MBBCh, discusses the optimal use of PD-1/PD-L1 monotherapy in prostate cancer.

Stereotactic Ablative Radiation Slows Progression in Oligometastatic Prostate Cancer

March 27th 2020

Stereotactic ablative radiation reduced disease progression compared with observation in patients with oligometastatic prostate cancer.

Dr. McKay on Rationale for Real-World Analysis of Radium-223 in mCRPC

March 27th 2020

Rana R. McKay, MD, discusses the rationale for conducting a real-world analysis of radium-223 dichloride in metastatic castration-resistant prostate cancer.

Dr. Freedland on Real-World Evidence Vs PREVAIL Trial in mCRPC

March 27th 2020

Stephen J. Freedland, MD, discusses how real-world evidence with the use of enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) compares with data from the phase III PREVAIL trial.

Dr. Gomella on Screening Recommendations in Prostate Cancer

March 27th 2020

Leonard G. Gomella, MD, discusses recommendations for screening in prostate cancer.

Dr. Tagawa on Safety Profile of 225Ac-J591 in mCRPC

March 27th 2020

Scott T. Tagawa, MD, MS, discusses the safety profile of novel monoclonal antibody 225Ac-J591 in metastatic castration-resistant prostate cancer.

Dr. Grivas on the Role of Targeted Therapy in Prostate Cancer

March 27th 2020

Petros Grivas, MD, PhD, discusses the role of targeted therapy in prostate cancer.

Long-Term Follow-Up Validates Noninferiority Between Radiation Regimens in Prostate Cancer

March 25th 2020

Moderate hypofractionated intensity-modulated radiation therapy did not show biochemical and/or clinical disease failure rate superiority compared with conventionally fractioned IMRT for men with intermediate- and high-risk prostate adenocarcinoma.

68Ga-PSMA-11 PET Imaging Poised to Be Useful Management Tool in Biochemically Recurrent Prostate Cancer

March 25th 2020

Wolfgang Fendler, MD, highlights the potential impact 68Ga-PSMA-11 PET imaging may have on the treatment of patients with biochemically recurrent prostate cancer.

Dr. Cone on Evaluating the Relative Cardiac Risk of GnRH Agonists Versus Antagonists in Prostate Cancer

March 23rd 2020

Eugene B. Cone, MD, a urologic oncology fellow at Brigham and Women’s Hospital and Massachusetts General Hospital, discusses the methods that were used to evaluate the relative cardiac risk of gonadotropin-releasing hormone (GnRH) agonists versus antagonists in patients with prostate cancer.

Dr. Graff on the KEYNOTE-641 Trial in mCRPC

March 23rd 2020

Julie N. Graff, MD, associate professor of medicine, Oregon Health & Science University Knight Cancer Institute, discusses the phase III KEYNOTE-641 trial in metastatic castration-resistant prostate cancer (mCRPC).

Dr. Armstrong on Detection of Chromosomal Defects in mCRPC

March 21st 2020

Andrew J. Armstrong, MD, discusses the use of circulating tumor cell to detect chromosomal instability in men with metastatic castration-resistant prostate cancer.

Cell-Free DNA Shows Potential in Identifying Transformed Castration-Resistant Neuroendocrine Prostate Cancer

March 20th 2020

Himisha Beltran, MD, discusses research evaluating cell-free DNA to identify therapy resistance in prostate cancer.

Dr. Hamid on the Exploration of Predictive Biomarkers in mHSPC Subtypes

March 20th 2020

Anis Hamid, MBBS, discusses the hypothesis of predictive biomarkers for newly diagnosed metastatic hormone sensitive prostate cancer.

Rapid Sequencing May Alleviate Sequencing Challenges in mCRPC

March 20th 2020

William K. Oh, MD, discusses sequencing challenges in prostate cancer, biomarker development, and the impact of the PRINT trial.

Dr. Armstrong on the Utility of AR-V7 as a Biomarker in Prostate Cancer

March 20th 2020

Andrew J. Armstrong, MD, discusses the utility of AR-V7 as a biomarker in prostate cancer.

Dr. Gomella on the Evolution of AR Inhibitors in Prostate Cancer

March 19th 2020

Leonard G. Gomella, MD, professor, chair of the Department of Urology, and director of the Sidney Kimmel Cancer Center Network, of Thomas Jefferson University Hospital, discusses the evolution of androgen receptor (AR) inhibitors in prostate cancer.

GnRH Antagonists Lead to Lower Odds of Cardiac Complications in Prostate Cancer

March 19th 2020

Eugene B. Cone, MD, discusses the advantages of the study, the need for such research, and the potential to broaden these efforts to more novel agents such as abiraterone acetate, enzalutamide, and immune checkpoint inhibitors.

mCRPC: Advice for Treatment During COVID-19

March 18th 2020